Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taselisib plus fulvestrant versus placebo plus fulvestrant in PIK3CA-mutant ER-positive HER2-negative advanced breast cancer
NL-OMON45216Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Taselisib plus fulvestrant with Placebo plus fulvestrant (2 arms). Primary endpoint: Investigator-assessed progression-free survival. Started Nov 2015; status: active, not recruiting.
02
Drugs
taselisib / pictilisibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON45216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45216.